Education
About Us
Working with TipRanks
Follow Us
Clarity Pharmaceuticals Ltd. (AU:CU6)
ASX:CU6
RESEARCH TOOLSreports
Total Valuation
Clarity Pharmaceuticals Ltd. has a market cap or net worth of AU$800.17M. The enterprise value is ―.
Market CapAU$800.17M
Enterprise Value―
Share Statistics
Clarity Pharmaceuticals Ltd. has 321,351,620 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding321,351,620
Owned by Insiders13.02%
Owned by Institutions―
Financial Efficiency
Clarity Pharmaceuticals Ltd.’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -30.79%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-30.79%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee230.13K
Profits Per Employee-846.49K
Employee Count50
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Clarity Pharmaceuticals Ltd. is -33.17. Clarity Pharmaceuticals Ltd.’s PEG ratio is 2.37.
PE Ratio-33.17
PS Ratio0.00
PB Ratio6.05
Price to Fair Value9.60
Price to FCF-16.61
Price to Operating Cash Flow-16.45
PEG Ratio2.37
Income Statement
In the last 12 months, Clarity Pharmaceuticals Ltd. had revenue of 11.51M and earned -42.32M in profits. Earnings per share was -0.15.
Revenue11.51M
Gross Profit11.51M
Operating Income-44.80M
Pretax Income-42.03M
Net Income-42.32M
EBITDA-44.65M
Earnings Per Share (EPS)-0.15
Cash Flow
In the last 12 months, operating cash flow was -46.84M and capital expenditures -103.86K, giving a free cash flow of -47.01M billion.
Operating Cash Flow-46.84M
Free Cash Flow-47.01M
Free Cash Flow per Share-0.15
Dividends & Yields
Clarity Pharmaceuticals Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.18
52-Week Price Change-39.61%
50-Day Moving Average2.29
200-Day Moving Average4.92
Relative Strength Index (RSI)56.89
Average Volume (3m)2.99M
Important Dates
Clarity Pharmaceuticals Ltd. upcoming earnings date is Aug 20, 2025, TBA Not Confirmed.
Last Earnings DateFeb 28, 2025
Next Earnings DateAug 20, 2025
Ex-Dividend Date―
Financial Position
Clarity Pharmaceuticals Ltd. as a current ratio of 19.05, with Debt / Equity ratio of 0.00%
Current Ratio19.05
Quick Ratio19.05
Debt to Market Cap0.00
Net Debt to EBITDA1.07
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Clarity Pharmaceuticals Ltd. has paid 295.15K in taxes.
Income Tax295.15K
Effective Tax Rate>-0.01
Enterprise Valuation
Clarity Pharmaceuticals Ltd. EV to EBITDA ratio is -30.37, with an EV/FCF ratio of -31.00.
EV to Sales117.86
EV to EBITDA-30.37
EV to Free Cash Flow-31.00
EV to Operating Cash Flow-31.37
Balance Sheet
Clarity Pharmaceuticals Ltd. has AU$111.19M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of -AU$111.19M billion.
Cash & Marketable SecuritiesAU$111.19M
Total DebtAU$0.00
Net Cash-AU$111.19M
Net Cash Per Share-AU$0.35
Tangible Book Value Per ShareAU$0.54
Margins
Gross margin is 100.00%, with operating margin of -389.35%, and net profit margin of -367.83%.
Gross Margin100.00%
Operating Margin-389.35%
Pretax Margin-365.26%
Net Profit Margin-367.83%
EBITDA Margin-388.02%
EBIT Margin-389.35%
Analyst Forecast
The average price target for Clarity Pharmaceuticals Ltd. is AU$6.22, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetAU$6.22
Price Target Upside146.83% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-40.19%